XTL Biopharmaceuticals Ltd. (XTLB) Financial Ratios
22 years of historical data (2003–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High0.1
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
0.07
↓-58% vs avg
5yr avg: 0.16
30Y Low0.1·High79.4
ROE
↓
-26.8%
↑-123% vs avg
5yr avg: -12.0%
30Y Low-185%·High361%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
XTLB Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
XTL Biopharmaceuticals Ltd. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $357581 | $893403 | $343970 | $412087 | $1M | $973769 | $440285 | $555980 | $672949 | $539507 | $1M |
| Enterprise Value | $124581 | $660403 | $-1057030 | $-1681913 | $-1903337 | $-2657231 | $-4014715 | $-2699020 | $-2616051 | $-1479493 | $-2654963 |
| P/E Ratio → | -0.34 | — | — | — | 2.47 | — | — | 0.19 | — | — | — |
| P/S Ratio | 0.79 | 1.98 | — | — | — | — | — | — | — | — | — |
| P/B Ratio | 0.07 | 0.16 | 0.15 | 0.10 | 0.20 | 0.16 | 0.06 | 0.07 | 0.19 | 0.20 | 0.24 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
XTLB EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.46 | — | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
XTLB Profitability
Margins and return-on-capital ratios measuring operating efficiency
XTL Biopharmaceuticals Ltd. earns an operating margin of -481.6%. A negative ROE of -26.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 0.7% | 0.7% | — | — | — | — | — | — | — | — | — |
| Operating Margin | -481.6% | -481.6% | — | — | — | — | — | — | — | — | — |
| Net Profit Margin | -227.7% | -227.7% | — | — | — | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -26.8% | -26.8% | -0.1% | -28.9% | 7.5% | -11.8% | -17.6% | 50.0% | -24.8% | -67.2% | -90.1% |
| ROA | -18.7% | -18.7% | -0.1% | -25.0% | 6.6% | -11.4% | -17.1% | 39.4% | -16.3% | -61.0% | -78.6% |
| ROIC | -54.1% | -54.1% | -42.1% | -30.9% | -31.0% | -27.6% | -16.6% | -22.0% | -187.3% | -221.0% | -150.9% |
| ROCE | -50.7% | -50.7% | -24.6% | -16.9% | -16.3% | -14.3% | -11.0% | -10.9% | -27.8% | -67.6% | -75.5% |
XTLB Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $371000 exceeds total debt of $138000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | — | — | — | — | — | — | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.04 | -0.63 | -0.52 | -0.56 | -0.58 | -0.64 | -0.39 | -0.91 | -0.75 | -0.78 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -13.13 | -13.13 | -191.30 | -80.01 | -49.10 | -55.77 | -29.03 | -113.29 | -155.75 | — | — |
Net cash position: cash ($371000) exceeds total debt ($138000)
XTLB Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.61x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 20.35x to 0.61x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.61 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.69 | 8.35 | 9.78 |
| Quick Ratio | 0.61 | 0.61 | 9.93 | 20.35 | 27.00 | 24.10 | 29.44 | 32.39 | 20.40 | 7.95 | 9.78 |
| Cash Ratio | 0.52 | 0.52 | 9.74 | 19.90 | 26.52 | 23.79 | 29.00 | 32.10 | 20.31 | 7.37 | 9.33 |
| Asset Turnover | — | 0.05 | — | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 80.12 | — | — | — | — | — | — | — | — | — |
XTLB Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
XTL Biopharmaceuticals Ltd. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | 40.4% | — | — | 536.4% | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $110025 | $85141 | $85142 | $96179 | $80344 | $80344 | $80344 | $73466 | $42818 | $41207 |
Peer Comparison
Compare XTLB with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 XTLBYou | $357581 | -0.3 | — | — | 0.7% | -481.6% | -26.8% | -54.1% | — |
 NRXP | $84M | -2.3 | — | — | — | -1324.4% | — | — | — |
 SIGA | $337M | 14.2 | -6387033.2 | 6.9 | 68.0% | 25.1% | 0.0% | 0.0% | 0.0 |
 BFRI | $13M | — | — | — | 75.8% | -27.2% | -141.3% | -124.3% | — |
 AEYE | $95M | -30.6 | — | — | 78.3% | -7.9% | -43.2% | -42.4% | — |
 AVXL | $310M | -6.2 | — | — | — | — | -43.1% | — | — |
 INVA | $2B | 6.8 | 8.0 | 9.8 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 PRAX | $8B | -25.1 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.4 | 25.6 | 35.0 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 CORT | $6B | 63.6 | 117.5 | 39.5 | 98.3% | 5.9% | 15.0% | 6.2% | 0.1 |
 ALDX | $105M | -1.9 | — | — | — | — | -58.5% | -369.4% | — |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 22 years · Updated daily
See XTLB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XTLB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare XTLB vs NRXP
Side-by-side business, growth, and profitability comparison vs NRx Pharmaceuticals, Inc..
Start ComparisonXTLB — Frequently Asked Questions
Quick answers to the most common questions about buying XTLB stock.
What is XTL Biopharmaceuticals Ltd.'s P/E ratio?
XTL Biopharmaceuticals Ltd.'s current P/E ratio is -0.3x. The historical average is 1.0x.
What is XTL Biopharmaceuticals Ltd.'s ROE?
XTL Biopharmaceuticals Ltd.'s return on equity (ROE) is -26.8%. The historical average is -34.0%.
Is XTLB stock overvalued?
Based on historical data, XTL Biopharmaceuticals Ltd. is trading at a P/E of -0.3x. Compare with industry peers and growth rates for a complete picture.
What are XTL Biopharmaceuticals Ltd.'s profit margins?
XTL Biopharmaceuticals Ltd. has 0.7% gross margin and -481.6% operating margin.